ClinicalTrials.gg
Active, not recruitingNCT04900792XACT-Fe-GBM-01Updated Jul 20, 2026Results posted

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

A Phase 1 interventional study of Ferumoxytol injection and Pharmacological ascorbate in Glioblastoma and Glioblastoma Multiforme, sponsored by Bryan Allen. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Bryan Allen · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Enrollment
177th of 221
16 · median 41
Started
2023
with 2 others
Phase 1
70 of 232
3 open now
Primary completion
2025-05
later than 5 of 34 live
Registered
206th of 232
by date

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 177th largest by enrollment of the 221 interventional ones that give a count, is one of 3 that started in 2023, is one of 70 in phase 1, reaches primary completion later than 5 of the 34 other live ones, and was the 206th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.

Read the detailed description

The initial, standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth).

Participants in this trial will:

  • receive intravenous (IV) ferumoxytol the day before starting radiation, then around radiation treatments 6, 25, and 31.
  • receive high doses of intravenous (IV) ascorbate three times a week during the combined radiation and chemotherapy phase.
  • provide feedback about how they feel and their quality of life. This is done through short surveys as well as discussing with the study team.
03

Conditions studied

  • Glioblastoma
  • Glioblastoma Multiforme

Browse trials for

Keywords

  • ascorbate
  • radiation therapy
  • temozolomide
  • ferumoxytol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willingness and ability to provide consistent with Good Clinical Practice (i.e., legally authorized representative will not be used / allowed for this study).
  • Stated willingness to comply with all study procedures for the duration of the study
  • Aged 18 years or older.
  • Newly diagnosed (i.e., within 6 weeks), histologically or molecularly confirmed glioblastoma or diffuse midline glioma.
  • Therapy to begin within 6 weeks of last surgery
  • Able to take oral medication
  • performance status of 0, 1, or 2 ( of >50)
  • Recommended to receive temozolomide and radiation therapy
  • Medically fit, as determined by the prescribing oncologists, to undergo temozolomide and radiation therapy.
  • Agree to use of highly effective from screening until at least 90 days after the last study treatment (study participant should not discontinue contraception until discussing with their treating oncologist(s)).
  • Not have significant co-morbid central nervous system disease, such as multiple sclerosis.
  • Agree to Lifestyle Considerations throughout study duration

Exclusion criteria

Exclusion Criteria:

  • Current use of the following drugs and cannot have a drug substitution or decline the drug substitution: warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide. Pharmacologic ascorbic acid may affect urine acidification and, as a result, may affect clearance rates of these drugs.
  • Current use of antiretroviral drugs (e.g., nelfinavir, abacavir, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, zidovudine). Pharmacologic ascorbate acid is a known CYP450 3A4 inducer, which results in lower serum levels of antiretroviral drugs.
  • Insulin requirement
  • Requires blood glucose monitoring using finger-stick glucose checks.
  • Medical requirement or indication for iron supplementation (including ferumoxytol, ferrous gluconate, ferrous fumarate, or ferrous sulfate). NOTE: Over the counter, patient-elective supplementation is acceptable.
  • Inability to undergo MR imaging.
  • Pregnancy or lactation (note: potential participants should not engage in 'pump \& dump' strategy; lactation must be discontinued).
  • Known allergic reactions to ferumoxytol.
  • History of Steven's Johnson Syndrome
  • History of hemochromatosis.
  • Prior radiation treatment that would result in field overlap. For potential participants who have undergone nuclear medicine therapy, including PRRT, the study's radiation oncologist must approve study entry.
  • G6PD (glucose-6-phosphate dehydrogenase) deficiency
  • count \< 100,000 /mm3 within 21 days of first treatment
  • Creatinine ≥ 1.5x the institutional within 21 days of the first treatment or if creatinine is elevated a of \< 60 mL/(min 1.73 m2)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (requiring inpatient admission or a delay to start of therapy), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Treatment with another drug within 30 days prior to study treatment day 1. Imaging trials (including investigational PET or NM tracers) as well as observational trials are acceptable.
  • Clinical trials with an endpoint of treating the patient's cancer, including behavioral, nutritional and/or device human subject studies.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort 1 (starting)

    Radiation Phase * Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks. * Ferumoxytol: 512 g administered intravenously (IV) the day before radiation and then during weeks 5 to 6 of radiation therapy. * Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks) * Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first). Adjuvant Phase * Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles * Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle * Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of chemotherapy.

    Drug: Ferumoxytol injection · Drug: Pharmacological ascorbate · Radiation: External beam radiation therapy · Drug: Temozolomide

  • Experimental
    Cohort 2

    Radiation Phase * Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks. * Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, about 1 week after dose 1, during weeks 5 to 6 of radiation therapy, and then a week after that (for a total of 4 ferumoxytol infusions). * Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks) * Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first). Adjuvant Phase * Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles * Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle * Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of

    Drug: Ferumoxytol injection · Drug: Pharmacological ascorbate · Radiation: External beam radiation therapy · Drug: Temozolomide

Interventions

  • DrugFerrosoferric OxideStudies of Ferrosoferric OxideFerrosoferric Oxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.

    Also known as: Feraheme, Ferumoxytol

  • DrugAscorbic AcidStudies of Ascorbic AcidAscorbic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous ascorbate

    Also known as: ASCOR, vitamin C, ascorbic acid

  • RadiationExternal beam radiation therapy

    Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.

    Also known as: EBRT, radiotherapy, VMAT

  • Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.

    Also known as: Temodar, temozolomide capsule

06

What researchers measure

Primary outcomes

  1. Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)

    The recommended dose will be determined by incidence of dose limiting toxicities.

    Time frame: From treatment day 1 through 12 weeks after completing radiation

Secondary outcomes

  1. Estimate Progression Free Survival (PFS)

    Time (measured in months) to documented disease progression in MRI imaging as described by the RANO criteria.

    Time frame: From treatment day 1 to disease progression, up to 16 months post-treatment

  2. Estimate Overall Survival (OS)

    Time to death from any cause.

    Time frame: Time (measured in months) until death from any cause, up to 26 months post-treatment

  3. Disease Response

    Disease response and tumor measurements over time were assessed using Response Assessment in Neuro-Oncology (RANO) criteria in conjunction with the Neurologic Assessment in Neuro-Oncology (NANO) beginning 12 weeks after completion of radiation therapy, using radiation simulation MRI/CT as baseline. RANO disease response categories included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Tumor measurements obtained during radiographic assessment were incorporated into the overall RANO response evaluation.

    Time frame: 12 weeks post-radiation

  4. Number of Participants With Treatment-Related Adverse Events

    Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (v5). Treatment-related adverse events were categorized by toxicity type, including liver function, hematologic, and non-hematologic events. Participants were counted once per toxicity category if they experienced at least one treatment-related adverse event within that category during the study period.

    Time frame: Up to 36 months post-radiation

07

Results

Posted Jul 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2
Started79
Completed66
Not completed13
Withdrew: Did not meet compliance11
Withdrew: Physician decision01
Withdrew: Travel and time commitment restraints01

Outcome measures

PrimaryNumber of Ferumoxytol-related Dose Limiting Toxicities (DLTs)

The recommended dose will be determined by incidence of dose limiting toxicities.

Time frame:
From treatment day 1 through 12 weeks after completing radiation
Reported as:
Number · Dose Limiting Toxicities
Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)
Dose Limiting ToxicitiesCohort 1Cohort 2
Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)20
SecondaryEstimate Progression Free Survival (PFS)

Time (measured in months) to documented disease progression in MRI imaging as described by the RANO criteria.

Time frame:
From treatment day 1 to disease progression, up to 16 months post-treatment
Reported as:
Median · months
Estimate Progression Free Survival (PFS)
monthsCohort 1Cohort 2
Estimate Progression Free Survival (PFS)8 (4 to 12)6 (4 to 16)
SecondaryEstimate Overall Survival (OS)

Time to death from any cause.

Time frame:
Time (measured in months) until death from any cause, up to 26 months post-treatment
Reported as:
Median · Months
Estimate Overall Survival (OS)
MonthsCohort 1Cohort 2
Estimate Overall Survival (OS)12 (9 to 26)13 (7 to 19)
SecondaryDisease Response

Disease response and tumor measurements over time were assessed using Response Assessment in Neuro-Oncology (RANO) criteria in conjunction with the Neurologic Assessment in Neuro-Oncology (NANO) beginning 12 weeks after completion of radiation therapy, using radiation simulation MRI/CT as baseline. RANO disease response categories included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Tumor measurements obtained during radiographic assessment were incorporated into the overall RANO response evaluation.

Time frame:
12 weeks post-radiation
Reported as:
Count of participants · Participants
Disease Response
ParticipantsCohort 1Cohort 2
Progressive Disease (PD)11
Complete Response (CR)00
Stable Disease (SD)45
Partial Response (PR)00
SecondaryNumber of Participants With Treatment-Related Adverse Events

Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (v5). Treatment-related adverse events were categorized by toxicity type, including liver function, hematologic, and non-hematologic events. Participants were counted once per toxicity category if they experienced at least one treatment-related adverse event within that category during the study period.

Time frame:
Up to 36 months post-radiation
Reported as:
Number · participants
Number of Participants With Treatment-Related Adverse Events
participantsCohort 1Cohort 2
Liver function56
Hematologic56
Non-Hematologic56

Adverse events

Collected over Adverse event data were collected from treatment initiation through 36 months post-radiation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 15/6 (83.3%)1/6 (16.7%)6/6 (100%)
Cohort 24/6 (66.7%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2
Alanine aminotransferase increasedInvestigations1/60/6
SeizureNervous system disorders0/61/6
Most frequent other events
Showing 10 of 94
Most frequent other events
EventCohort 1Cohort 2
ConstipationGastrointestinal disorders3/66/6
Dry mouthGastrointestinal disorders5/66/6
ChillsGeneral disorders4/66/6
FatigueGeneral disorders4/66/6
Alanine aminotransferase increasedInvestigations2/66/6
Lymphocyte count decreasedInvestigations5/66/6
AnemiaBlood and lymphatic system disorders5/61/6
NauseaGastrointestinal disorders5/64/6
Aspartate aminotransferase increasedInvestigations4/65/6
Platelet count decreasedInvestigations1/65/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Total
<=18 years000
Between 18 and 65 years5510
>=65 years112
Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Total
Mean59 (51 to 71)60 (52 to 68)59 (51 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female123
Male549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino000
Not Hispanic or Latino6612
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White6612
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Total
United States6612
08

Study locations

1 site
  • Department of Radiation Oncology at University of Iowa
    Iowa City, Iowa 52242, United States
09

References and documents

Publications

  • Allen BG, Bodeker KL, Smith MC, Monga V, Sandhu S, Hohl R, Carlisle T, Brown H, Hollenbeck N, Vollstedt S, Greenlee JD, Howard MA, Mapuskar KA, Seyedin SN, Caster JM, Jones KA, Cullen JJ, Berg D, Wagner BA, Buettner GR, TenNapel MJ, Smith BJ, Spitz DR, Buatti JM. First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma. Clin Cancer Res. 2019 Nov 15;25(22):6590-6597. doi: 10.1158/1078-0432.CCR-19-0594. Epub 2019 Aug 19. PubMed 31427282 ↗
  • Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. PubMed 28366679 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data will be released publicly as per participant consent and IRB approval. Individual researchers should contact the research team for data sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Study protocol and informed consent will be shared after primary completion. Statistical analysis plan will be shared with results reporting.

Access criteria: An IRB-stamped signed usage agreement will be required in addition to a data sharing agreement between the academic centers.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in May 2025, 26 months.

Results were first posted in Jul 2026, 1 year 2 months after primary completion.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 26 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2021
First posted
May 25, 2021
StartActual
Feb 28, 2023
Primary completionActual
May 13, 2025
CompletionEst.
Dec 31, 2026
Results first posted
Jul 20, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04900792
Lead sponsor
Bryan Allen
Collaborators
Holden Comprehensive Cancer Center, National Cancer Institute (NCI)
Responsible party
Bryan Allen (Associate Professor, University of Iowa) — Sponsor-investigator
First posted
May 25, 2021
Start date
Feb 28, 2023
Primary completion
May 13, 2025
Completion
Dec 31, 2026 (estimated)
Results posted
Jul 20, 2026
Last update
Jul 20, 2026

Study contacts

John M. Buatti, MD
study director · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ferrosoferric Oxide · Temozolomide

Start the discussion